GSK’s new $32,500 asthma med costs at least 2X too much, U.S. pricing watchdog says

Carly Helfand GlaxoSmithKline has a new drug that's tailored for patients with a specific type of severe asthma. But according to a nonprofit body that evaluates drugs' prices ...

With FDA nod, Actelion adds blockbuster hopeful Uptravi to PAH portfolio

Carly Helfand Actelion has been laboring to fill the void left by declining sales of aged pulmonary arterial hypertension (PAH) med Tracleer. And now, it has another tool ...

Alzheimer’s player Anavex reveals SEC probe; shares dive

John Carroll Shares of Anavex took a nasty hit after the New York-based biotech issued a 10-K this morning that included news of an SEC probe, evidently focused on "unusual" ...

Big Pharma’s steady double-digit price hikes cost Medicare billions

Tracy Staton A new report from the Center for Medicare and Medicaid Services highlights some commonly used meds whose sales growth–and Medicare spending–depends more on ...

Shire inches closer to Baxalta buy with cash-sweetened bid

Carly Helfand Shire has offered up a new bid for elusive target Baxalta that's more or less what the Illinois drugmaker has been looking for, reports say. But that doesn't ...

Pneumonia-stricken Valeant chief takes medical leave of absence

Carly Helfand Last week, Valeant confirmed that CEO J. Michael Pearson had been hospitalized with a severe case of pneumonia–and now, he's taking a medical leave of absence. FiercePharma ...

Chimerix shares crash as antiviral flops and deaths spike in first PhIII challenge

John Carroll High hopes for Chimerix's antiviral turned into a bad case of data shock Monday morning after the biotech revealed that brincidofovir had failed its first Phase III ...

Celgene opens door for early launch of Revlimid generics

Emily Wasserman Just in time for the holidays, Celgene settled the score with Natco Pharma over patents for its cancer blockbuster Revlimid. The company is allowing the Indian generics ...

Doctors target Catalyst Pharma’s forthcoming pricing on old-turned-new med Firdapse

Tracy Staton A new group of activist doctors has joined the drug pricing protests. This time, it's neuromuscular specialists, and they're targeting a forthcoming drug, Firdapse, ...

Boehringer Ingelheim will hire 400, invest €500M in Vienna biologics operation

Eric Palmer Germany's Boehringer Ingelheim has been swapping out operations and changing up top management as it scrambles to recover from patent losses that have flattened its ...

Adamas soars as its Parkinson’s drug comes through in Phase III

Damian Garde Adamas Pharmaceuticals' lead drug met its main goals of reducing side effects related to Parkinson's disease treatment in a late-stage trial, the company said, ...

Kamada’s rabies treatment clears Phase III with an FDA app on deck

Damian Garde Kamada's immunoglobulin treatment for rabies met its main goal in a late-stage trial, clearing the way for an FDA application next year. FierceBiotech News
Page 1 of 712345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS